Cyclacel Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on Cyclacel Pharmaceuticals Inc in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Cyclacel Pharmaceuticals Inc Strategy Report

  • Understand Cyclacel Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Cyclacel Pharmaceuticals Inc: Overview

Select Item

Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, PLK inhibitor and CDK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. The company’s seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.

 Gain a 360-degree view of Cyclacel Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Cyclacel Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 200 Connell Dr Ste 1500, Berkeley Heights, New Jersey, 07922-2811
Website cyclacel.com
Telephone 1 908 5177330
No of Employees 12
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange CYCC (NASD)
Revenue (2022) $420,000
EPS XYZ
Net Income (2022) XYZ -6.4% (2022 vs 2021)
Market Cap* $2.4M
Net Profit Margin (2022) XYZ 0.0% (2022 vs 2021)
* As of and is in US$
View Cyclacel Pharmaceuticals Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Cyclacel Pharmaceuticals Inc premium industry data and analytics

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Cyclacel Pharmaceuticals Inc’s relevant decision makers and contact details.

40+

Catalyst Calendar

Proactively evaluate Cyclacel Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Clinical Trials

Determine Cyclacel Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

16+

Pipeline Drugs

Identify which of Cyclacel Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products
Pipeline
Fadraciclib CDK Inhibitor (Oral) - Solid Tumors, Leukemias
Fadraciclib CDK Inhibitor (i.v.) - Solid Tumors, CLL, AML/MDS
XYZ
XYZ
XYZ
Understand Cyclacel Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Cyclacel Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Cyclacel Pharmaceuticals Inc Esperion Therapeutics Inc Abeona Therapeutics Inc GeneLink BioSciences, Inc. Deltagen Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Berkeley Heights Vero Beach Cleveland Elmsford Redwood City
State/Province New Jersey Florida Ohio New York California
No. of Employees 12 240 84 15 268
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Spiro Rombotis President; Chief Executive Officer; Director Executive Board 2021 64
Paul McBarron Chief Operating Officer; Executive Vice President - Finance; Secretary; Director Executive Board 2021 62
Brian Schwartz, M.D. Chief Medical Officer - Interim Senior Management 2024 -
Christopher S. Henney, Ph.D. Chairman Non Executive Board 2005 82
Robert J. Spiegel, M.D Vice Chairman Senior Management 2018 73
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Cyclacel Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Cyclacel Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward